The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I correctly anticipated the share price drop here today way before the market even opened to trade. Many have indeed sold their shares.
The share price will keep on falling if there are no substantial developments here in due course in the form of an official market update.
And you can report me for expressing my opinion (strong sell) on this share but we are all entitled to our own opinions.
Good luck with your investments.
£1 million traded in the first half hour!!!!
SEA OF BLUE!!!!
We will get past multiple of pennies at this rate!
1 pence will be smashed really soon.
Most probably in the first hour of trading.
Just wait and see.
A rare opportunity presents itself here.
I just bought £5,000 worth of these.
If sales remain steady at this rate for each quarter then that's an annual revenue of £18 million. However, sales are most like going to increase in my opinion.
Matt Sassone, CEO of LiDCO, said: "This ESICEM webinar has highlighted two key measurements to assist in the treatment of COVID-19 patients, the end expiratory occlusion test (EEOT) and tidal volume challenge (TVC), which LiDCO's technology already has in-built. This demonstrates once again the core benefits of our technology in the critical care environment and our technology leadership in the advanced hemodynamic monitoring market. I am proud of how our team met the challenge of a substantial surge in orders in Q1, thereby doing our part to help hospitals and patients affected by Covid-19."
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)
LiDCO Group Plc
("LiDCO" or the "Company")
Hemodynamic management in COVID-19 patients and Q1 sales update
LiDCO (AIM: LID), a leading supplier of hemodynamic monitoring solutions, welcomes the recent educational webinar from the European Society of Intensive Care Medicine ('ESICEM') regarding hemodynamic management in COVID-19 patients. The panel consisted of four international experts who discussed current World Health Organisation COVID-19 treatment guidelines and explored the patient benefits of using advanced hemodynamic monitoring in such treatment.
During the discussions, Senior Consultant Antonio Messina at Humanitas Hospital, Italy discussed the frontline strategies for treating COVID-19 patients and the importance of managing these ventilated patients' physiology with functional hemodynamic tests. During Dr Messina's speech he called out the importance of using a combination of a ventilator and a hemodynamic monitor to perform an end expiratory occlusion test ('EEOT') to assess the patient's fluid status.
This point was reinforced by Professor Jacques Duranteau, Head of Anaesthesia and Critical Care at Bicetre hospital, Paris, who referenced the need to employ a conservative fluid strategy and discussed the use of another ventilator-associated method, the tidal volume challenge ('TVC'), as a means to assess a patient's fluid status to prevent giving COVID-19 patients any excess fluid.
To perform these tests requires a precise measurement of the patient's advanced hemodynamic parameters. The LiDCO monitor is able to meet this need to measure these small changes over a short period of time and is the only monitor on the market to have both the EEOT and TVC as in-built guided clinical protocols.
As previously announced in LiDCO's Full-Year Results release in April 2020, the Company has seen a strong lift in demand for its hemodynamic monitoring systems due to COVID-19. Over 200 monitors have been sold, predominately in the UK, in the first three months of the financial year compared with 219 sold in the whole of previous financial year. LiDCO has been able to supply the monitors to ICU units around the world where patients with the most acute symptoms of COVID-19 are being treated.
LiDCO sales in Q1 of this year (three months ended 30 April 2020) were £4.4m up 179% on the corresponding period last year. As expected, Q1 sales have therefore already significantly exceeded the total sales of £3.5m the Company achieved in H1 last year (6 months to 31 July 2019).
To listen to the ESICEM webinar click here: https://bit.ly/2VDerOI
To find out more information about EEOT and TVC click here: http://www.lidco.com/what-are-preload-responsive-ventilator-tests/
Matt Sassone, CEO of LiDCO, said: "This ESICEM webinar has highlighted two key measurement
HUGE RISE COMING
CGNR is about to lift off!!! Expecting one bag (100% gain)!!!
Gold discovery!!!
CGNR is about to lift off!!! Expecting one bag (100% gain)!!!
Gold discovery!!!
CGNR is about to lift off!!! Expecting one bag (100% gain)!!!
Gold discovery!!!
CGNR is about to lift off!!! Expecting one bag (100% gain)!!!
Gold discovery!!!
STRONG BUY
20 PENCE TODAY
20 pence is the next price level.
Some are still clueless and sound asleep on this one. Oh well, there's still plenty of time to read the RNSs and get in if you have half a brain. This share really is s no-brainer at the moment.
NCTY Is currently valued at almost £300m.
HEMO isn't even valued at £100m yet.
This should be valued at one third (1/3) of NCYT given the prospects here.
9 pence per share equates to an mc of £35m.
25p would equate to an mc of £100m.
Still another £75m to be added the to the market capitalisation here.
This should be trading at 25p at an mc of £100m.